英语新闻｜2种新冠药品纳入医保，辉瑞因“报价高”未能进入

英语新闻｜2种新冠药品纳入医保，辉瑞因“报价高”未能进入

Pfizer's COVID-19 treatment Paxlovid will not be added to China's updated medical reimbursement list because the company asked for a very high price during the latest round of price negotiations that wrapped up on Sunday, the National Healthcare Security Administration said on Sunday.

据国家医疗保障局最新公告，在1月8日结束的最新一轮价格谈判中，Paxlovid因生产企业辉瑞投资有限公司报价高未能成功入选最新的医疗报销清单。

However, drugmakers of two other COVID-19 therapies — the homegrown Azvudine and the Qingfei paidu granule, a widely used traditional Chinese medicine to ease COVID-19 symptoms — have successfully struck a deal during the negotiation, said the administration.

然而，另外两种缓解新冠肺炎症状的中药，阿兹夫定片、清肺排毒颗粒谈判成功。

With the two additions, the administration said that the medical reimbursement list will contain more than 600 types of drugs that have been proven to alleviate fevers, coughing and other COVID-19 symptoms.

阿兹夫定片、清肺排毒颗粒经过本次谈判纳入国家医保药品目录后，国家医保药品目录内治疗发热、咳嗽等新冠症状的药品已达600余种。

Local healthcare security authorities have also included a number of COVID-19 drugs to their temporary reimbursement lists based on the capacity of local funds.

近期各地医保部门结合当地医保基金运行情况，又将一批新冠对症治疗药物临时纳入本地区医保支付范围。

Although the highly-anticipated inclusion of Paxlovid was not achieved, the administration said that all COVID-19 drugs listed in the latest version of COVID-19 treatment protocol, including Paxlovid and Merck's Molnupiravir, will be reimbursed through to March 31.

尽管大家期待的辉瑞Paxlovid未能成功纳入清单，但有关部门表示，最新版本的新冠肺炎治疗方案中列出的所有药物，包括Paxlovid和默克公司研发的Molnupiravir，患者在2023年3月31日前均可享受到相关的医保报销政策。

"We have a rich variety of reimbursable drugs used to treat COVID-19," it said.

根据国家医疗保障局最新公告，总体来看，医保报销的新冠病毒感染治疗用药品种丰富。

Drugmaker

英 [ˈdrʌɡˌmeɪkə]  美 [ˈdrʌɡˌmekər]

n. 制药者

Alleviate

英 [əˈliːvieɪt]  美 [əˈliːvieɪt]

v. 减轻、缓和

Reimbursement

英 [ˌriːɪmˈbɜːsmənt]  美 [ˌriːɪmˈbɜːrsmənt]

n. 报销